Lesinuard(RDEA594) Pharma Grade
878672-00-5
Pharmaceutical Grade
SHANGHAI
1kg/0.12kg Bag
2017-06-29
CAL-101 Tedizolid Afatinib Nintedanib Lenvatinib,Neratinib Olaparib Rucaparib and intermediates
-
Product Description
-
Seller Information
-
Description
Chemical Information
Product name: Lesinurad（RDEA594)
Synonyms: 2-[[5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid; RDEA 594
CAS No.: 878672-00-5
Molecular Formula: C17H14BrN3O2S
Molecular weight: 404.28
Technicel Data
Appearance: Tech pack
purity: 99.0%min
Solubility: DMSO
Package: Packaging according to customer requirements
Storage: −20°C 2 years
Shipping condition: Conventional transport
http://www.shinningpharm.com/products_detail_e/id/29.html
ECHEMI Editorial ReferenceLesinurad is a URAT1 and OAT inhibitor, is determined to be a substrate for the kidney transporters OAT1 and OAT3 with Km values of 0.85 and 2 µM, respectively.
Lesinurad is a member of the class of triazoles that is [(3-bromo-1,2,4-triazol-5-yl)sulfanyl]acetic acid substituted at position 1 of the triazole ring by a 4-cyclopropylnaphthalen-1-yl group. Used for treatment of gout. It has a role as a uricosuric drug. It is a member of triazoles, a member of naphthalenes, a member of cyclopropanes, an organobromine compound, an aryl sulfide and a monocarboxylic acid.|Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with diuretic-induced hyperuricemia. Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In August 2017, a combination oral therapy consisting of lesinurad and [DB00437] was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with uncontrolled gout.|Lesinurad is an Urate Transporter 1 Inhibitor. The mechanism of action of lesinurad is as an Urate Transporter 1 Inhibitor, and Cytochrome P450 3A Inducer.|Lesinurad is a selective inhibitor of uric acid reabsorption which is used in combination with other agents in the therapy of gout. Lesinurad has had limited clinical use, but has not been associated with serum enzyme elevations during therapy or with instances of clinically apparent liver injury.Basic Info-
Product Name:
Lesinurad
Other Name:Acetic acid,2-[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-;Acetic acid,[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-;2-[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]acetic acid;Lesinurad;RDEA 594;2-[[5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid;Lesinida;Zurampic;READ 594;2-[[5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid
CAS No.:878672-00-5
Molecular Formula:C17H14BrN3O2S
InChIKeys:InChIKey=FGQFOYHRJSUHMR-UHFFFAOYSA-N
Molecular Weight:404.28096
Exact Mass:404.28
UNII:09ERP08I3W|Q59CAT99RS|73WY698HZ7
ATC Code:M04AA51|M04AB05|M - Musculo-skeletal system
Characteristics-
PSA:
93.3
XLogP3:4.7
Density:1.72±0.1 g/cm3
Boiling Point:643.7°C at 760 mmHg
Flash Point:343.1±34.3 °C
Refractive Index:1.776
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Warning
Hazard statement(s) H302 Harmful if swallowed
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
CAL-101 Tedizolid Afatinib Nintedanib Lenvatinib,Neratinib Olaparib Rucaparib and intermediates
-
Location:
Ningyang Fine Chemicial Industry Park , Tai'an, Shandong.
-
Payment Terms:
L/C,D/A
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
Shandong Shining Pharm Co., Ltd. is Investment and holding by a natural person, sets up three R&D Centers under Shining Pharm: Jinan Synovel Laboratory Co., Ltd., Tianjin Chemlike Scientific Co., Ltd. and Nanjing Leizheng Pharm Co., Ltd. Export agent: Taizhou Crene Biotechnology Co., Ltd. Our manufactory Located in Ningyang Fine Chemical Industry Park, Tai’an ,Shangdong province.
Shandong Shining Pharm is a high-tech manufactory, which is committed to producing high quality pharmaceutical intermediates, promoting innovation in API technology and provide customized services for global pharmaceutical companies, dedicates itself on research, develop and industrialize of high-end intermediates & API. We have three R&D centers from Ji’nan, Tianjin and Nanjing, more than 40 R&D staff including 5 doctors, 20 masters and 18 synthesis assistants, along with their unique advantages in the product development, pilot and process optimization, of total hundred employees. Our products are highly praised by global customers as we are Closed cooperation with domestic pharmaceutical companies, with International market of
Shandong Shining Pharm Covers an area of 40 mu (around 30000 square meter), located at Ningyang Fine Chemical Industry Park, Tai’an., which is a provincial chemical industry park, It is a high standard manufactory and about to set up cGMP quality system. Our plant including 500㎡ analysis laboratories equipped with HPLC, LC-MS, GC and other analytical facilities, one pilot and four mass production workshop, the total reaction capacity can reach 35000L which can meet commercial production demands from kilos to hundreds of tons, is perfect for analysis and production.
Shandong Shining Pharm provides the high-level products and the most reasonable price for our Partners. Our main products of intermediates: Idelalisib ints, Tedizolid ints, Afatinib ints, Nintedanib ints, Lenvatinib ints Trifluridine（ TAS-102）ints, etc.
“Social commitment, Professional services, Benefits society, Create better life” is Shandong Shining Pharm philosophy, Shandong Shining Pharm sincerely welcome global partners to get win-win cooperation, create a bright future!
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
More from this Seller
-
-
![Nintedanib (BIBF 1120) Pharma Grade]( "Nintedanib (BIBF 1120) Pharma Grade")
-
Nintedanib (BIBF 1120) Pharma Grade
Pharmaceutical Grade
-
-
-
![Tedizolid phosphate Pharma Grade]( "Tedizolid phosphate Pharma Grade")
-
Tedizolid phosphate Pharma Grade
Pharmaceutical Grade
-
-
-
![Idelalisib Pharma Grade]( "Idelalisib Pharma Grade")
-
Idelalisib Pharma Grade
Pharmaceutical Grade
-
-
-
![Tedizolid Pharma Grade]( "Tedizolid Pharma Grade")
-
Tedizolid Pharma Grade
Pharmaceutical Grade
-
-
-
![Nintedanib Ethanesulfonate Salt Pharma Grade]( "Nintedanib Ethanesulfonate Salt Pharma Grade")
-
Nintedanib Ethanesulfonate Salt Pharma Grade
Pharmaceutical Grade
-
-
-
![Afatinib Pharma Grade]( "Afatinib Pharma Grade")
-
Afatinib Pharma Grade
Pharmaceutical Grade
-
